Prifinium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Prifinium
Accession Number
DB13254
Description

Prifinium is an antimuscarinic agent with antispasmodic and antiemetic properties. It may be useful for the treatment of irritable bowel syndrome 1.

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 306.472
Monoisotopic: 306.221626326
Chemical Formula
C22H28N
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Prifinium.
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Prifinium.
AclidiniumThe risk or severity of adverse effects can be increased when Prifinium is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Prifinium.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Prifinium.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Prifinium.
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Prifinium.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Prifinium.
AlmotriptanAlmotriptan may increase the central nervous system depressant (CNS depressant) activities of Prifinium.
AlosetronAlosetron may increase the central nervous system depressant (CNS depressant) activities of Prifinium.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Ingredients
IngredientUNIICASInChI Key
Prifinium bromide3B7O9ZC5204630-95-9UCGJZJXOPSNTGZ-UHFFFAOYSA-M

Categories

ATC Codes
A03AB18 — Prifinium bromide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
N-alkylpyrrolidines / Tetraalkylammonium salts / Azacyclic compounds / Organopnictogen compounds / Organic salts / Hydrocarbon derivatives / Amines / Organic cations
Substituents
Amine / Aromatic heteromonocyclic compound / Azacycle / Diphenylmethane / Hydrocarbon derivative / N-alkylpyrrolidine / Organic cation / Organic nitrogen compound / Organic salt / Organoheterocyclic compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
3C7TTK1K7K
CAS number
10236-81-4
InChI Key
ZYEPZINLLPPBMI-UHFFFAOYSA-N
InChI
InChI=1S/C22H28N/c1-4-23(5-2)17-16-21(18(23)3)22(19-12-8-6-9-13-19)20-14-10-7-11-15-20/h6-15,18H,4-5,16-17H2,1-3H3/q+1
IUPAC Name
3-(diphenylmethylidene)-1,1-diethyl-2-methylpyrrolidin-1-ium
SMILES
CC[N+]1(CC)CCC(C1C)=C(C1=CC=CC=C1)C1=CC=CC=C1

References

General References
  1. Sasaki D, Suzuki A, Yoshida Y, Okamoto K, Ohmi T, Takahashi S, Yoshida S, Fukushi K, Higuchi K: Treatment of irritable bowel syndrome with prifinium bromide. Clin Ther. 1985;7(2):190-8. [PubMed:2859117]
ChemSpider
4736
RxNav
236174
ChEMBL
CHEMBL1229214

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00015 mg/mLALOGPS
logP3.99ALOGPS
logP0.7ChemAxon
logS-6.4ALOGPS
Physiological Charge1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity120.85 m3·mol-1ChemAxon
Polarizability37.24 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Drug created on June 23, 2017 14:38 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates